Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Obatoclax Mesylate (GX15-070) Chemical Structure

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • In vivo antitumor efficacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

    Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

     

    Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

    Cell death dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

    Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

     

     

    BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • MEF cells were treated for  24 hours with the Bcl-2 antagonists  Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

     

     

    Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot. 

    Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.
Features Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
Targets
Bcl-2 [1]
(Cell-free assay)
0.22 μM(Ki)
In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KARPAS-45 NHrOfZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTNWnZKSzVyPUCuNFAxODNzNzFOwG0> NF60dnNUSU6JRWK=
SK-MEL-30 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfOdWQ{UUN3ME2wMlAxODN3NTFOwG0> NHrW[3lUSU6JRWK=
NALM-6 M1HYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoqzTWM2OD1yLkCwNFM2PiEQvF2= Mn7DV2FPT0WU
KYSE-450 M{PTfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4O1fWlEPTB;MD6wNFA1PjlizszN NETxeZlUSU6JRWK=
BHY MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7HTWM2OD1yLkCwNFYxOSEQvF2= NWXDR3J4W0GQR1XS
GR-ST NWfQWIViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;jWYc1UUN3ME2wMlAxODZ2ODFOwG0> NILmWWFUSU6JRWK=
786-0 NEDCPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTjTWM2OD1yLkCwNFc4PiEQvF2= MonUV2FPT0WU
C-33-A M1;Kbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojmTWM2OD1yLkCwNFg1QCEQvF2= NX\oPWdiW0GQR1XS
BHT-101 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu1VmpKSzVyPUCuNFAyODZizszN NGnqXpVUSU6JRWK=
EB2 NXXLe2ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WwS2lEPTB;MD6wNFEyQCEQvF2= MkHrV2FPT0WU
G-361 MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS0TWM2OD1yLkCwNVI1KM7:TR?= MY\TRW5ITVJ?
KE-37 NIrVeZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMECxNlgh|ryP MXjTRW5ITVJ?
MHH-PREB-1 NIftc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMECxOEDPxE1? NXfTcm9HW0GQR1XS
MCF7 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;RfXBKSzVyPUCuNFAyPTlizszN MoX0V2FPT0WU
LOUCY MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLZTWM2OD1yLkCwNVc2KM7:TR?= M{C1UHNCVkeHUh?=
EW-7 M363Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7sSnk6UUN3ME2wMlAxOTd3IN88US=> NHzDbnhUSU6JRWK=
KYSE-510 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33WfmlEPTB;MD6wNFI{OyEQvF2= NYrNZldDW0GQR1XS
SK-MEL-3 Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17vdWlEPTB;MD6wNFI3PCEQvF2= M3PpT3NCVkeHUh?=
HAL-01 MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXNTWM2OD1yLkCwNlk4KM7:TR?= M33HeXNCVkeHUh?=
HCC2998 NHXMSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzmZodKSzVyPUCuNFA{OzVizszN NYPKTZBmW0GQR1XS
A375 NEnmTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;NeWVKSzVyPUCuNFA{PSEQvF2= MlzaV2FPT0WU
MZ7-mel NX7MZ3Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTjTWM2OD1yLkCwN|k6KM7:TR?= NVrtXlRQW0GQR1XS
SH-4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTLZlJwUUN3ME2wMlAxPDF5IN88US=> MULTRW5ITVJ?
HT-144 NXKyZVB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVi2fIlFUUN3ME2wMlAxPDNizszN MoH3V2FPT0WU
KYSE-140 MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTBwMEC0N|Uh|ryP MlnKV2FPT0WU
PSN1 NFr4SJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHxTWM2OD1yLkCwOFY4KM7:TR?= MoDrV2FPT0WU
COLO-679 M2H1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMEC0PVgh|ryP M2rldHNCVkeHUh?=
SW620 M2m3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTuTWM2OD1yLkCwOVEyKM7:TR?= NHe1TYFUSU6JRWK=
HGC-27 NGPiWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMEC1NlQh|ryP MkW5V2FPT0WU
IGROV-1 NVywV29XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LPN2lEPTB;MD6wNFYh|ryP Mn;5V2FPT0WU
IGR-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTBwMEC2NFEh|ryP MlvjV2FPT0WU
EW-1 NWHufpZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3KxXWlEPTB;MD6wNFY2OSEQvF2= NYTERXVoW0GQR1XS
769-P NHPhbnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrXO2FKSzVyPUCuNFA3PzhizszN M3rIc3NCVkeHUh?=
HN MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfocIs2UUN3ME2wMlAxPjd7IN88US=> MnvNV2FPT0WU
SIG-M5 MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmexTWM2OD1yLkCwO|Eh|ryP MYXTRW5ITVJ?
IST-MEL1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP3TWM2OD1yLkCwPFE5KM7:TR?= M3rD[nNCVkeHUh?=
ST486 NIP3cWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEC4NlUh|ryP NFjMXlNUSU6JRWK=
ES7 M{TzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;GN4twUUN3ME2wMlAxQDR4IN88US=> M{X0e3NCVkeHUh?=
GAK NG\xdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXIdpBoUUN3ME2wMlAxQDR6IN88US=> M3vsfHNCVkeHUh?=
BB30-HNC MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEC4OVgh|ryP MmDCV2FPT0WU
IPC-298 NUjhV|Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3NcnJsUUN3ME2wMlAxQTJ5IN88US=> NHKzfGtUSU6JRWK=
NKM-1 NUToZopmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3OwUGlEPTB;MD6wNFk4OiEQvF2= NVeybZlJW0GQR1XS
RKO MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fiVmlEPTB;MD6wNVA1PCEQvF2= NWXNcXYyW0GQR1XS
ACN NYHOd3MyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnoTWM2OD1yLkCxNVMyKM7:TR?= M3qzfXNCVkeHUh?=
SW1417 MoPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r3[WlEPTB;MD6wNVIzPSEQvF2= MXnTRW5ITVJ?
SR NYn6TnNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DIWmlEPTB;MD6wNVI{PSEQvF2= MkfkV2FPT0WU
SNG-M M{jremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fGb2lEPTB;MD6wNVMyPyEQvF2= NVzWUoI{W0GQR1XS
CAL-12T NGXB[JNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTBwMEGzOFYh|ryP MX\TRW5ITVJ?
HSC-3 NIO4[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4T4cWlEPTB;MD6wNVM2PSEQvF2= M2jDe3NCVkeHUh?=
DOHH-2 NV7JXoNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLaOWxKSzVyPUCuNFE1OTJizszN MknQV2FPT0WU
NB69 M{jSSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHHTWM2OD1yLkCxOVY2KM7:TR?= MXPTRW5ITVJ?
LC-2-ad M1jnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37MOWlEPTB;MD6wNVU5OSEQvF2= MXvTRW5ITVJ?
RVH-421 NWfQcoU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDOTWM2OD1yLkCxOlc1KM7:TR?= NGXMfJlUSU6JRWK=
TGW MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r4Z2lEPTB;MD6wNVc{QSEQvF2= M1vlXnNCVkeHUh?=
HCC1569 M3HqV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe1TGlKSzVyPUCuNFE4QTdizszN NVXab4tyW0GQR1XS
CAL-85-1 NYC5No1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPhSo1rUUN3ME2wMlAyQDN{IN88US=> MYXTRW5ITVJ?
RPMI-8402 M1jPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\HSGlEPTB;MD6wNVg2QCEQvF2= MVTTRW5ITVJ?
THP-1 Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\tU2lEPTB;MD6wNVk6QCEQvF2= M2DZXnNCVkeHUh?=
ONS-76 M4CyT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHRWIlLUUN3ME2wMlAzODN4IN88US=> NFznOHBUSU6JRWK=
A2780 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvqOmRKSzVyPUCuNFIxPzlizszN NGLybpRUSU6JRWK=
RPMI-2650 NH7Fb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwMEKyPVYh|ryP M1HmXXNCVkeHUh?=
MEL-HO NGG5UmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TXW2lEPTB;MD6wNlM1QCEQvF2= M3;Tc3NCVkeHUh?=
MC-CAR MonaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvtNplKSzVyPUCuNFI{PTZizszN MnvzV2FPT0WU
HSC-2 NEfBRm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwMEK0OlYh|ryP M{C3dXNCVkeHUh?=
MEL-JUSO M4jvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHCTWM2OD1yLkCyOFc{KM7:TR?= NYq2Zod2W0GQR1XS
CAL-62 NGrXZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfCTWM2OD1yLkCyOlAzKM7:TR?= MlXxV2FPT0WU
DMS-273 NF3kT2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwMEK4OFch|ryP MoP0V2FPT0WU
S-117 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTDTWM2OD1yLkCyPVA3KM7:TR?= MmC1V2FPT0WU
SUP-T1 NWHFVFl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXr1[WwzUUN3ME2wMlAzQTR7IN88US=> MnriV2FPT0WU
MZ2-MEL M3vu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:1UWlEPTB;MD6wNlk2QSEQvF2= M2q2OnNCVkeHUh?=
KYSE-270 NIPlN|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwMEK5O|Yh|ryP NWjJVGp6W0GQR1XS
CMK MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzHcXJKSzVyPUCuNFMxOjNizszN MlXDV2FPT0WU
8505C MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjNdZlKSzVyPUCuNFMxPCEQvF2= M4rwVXNCVkeHUh?=
NUGC-3 NEX3SJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LDW2lEPTB;MD6wN|A1QCEQvF2= Mk\rV2FPT0WU
A101D M3jUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn1R41KSzVyPUCuNFMxPTVizszN MoD4V2FPT0WU
G-401 NWXuTYMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq4XWpPUUN3ME2wMlA{ODl|IN88US=> MlvOV2FPT0WU
OVCAR-8 MkK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEOxNFch|ryP MlPvV2FPT0WU
IMR-5 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPXNFBKSzVyPUCuNFMzPDRizszN Ml3kV2FPT0WU
DoTc2-4510 M2XDdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnziTWM2OD1yLkCzN|k{KM7:TR?= M3G0UXNCVkeHUh?=
HOS M2jHTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PCXWlEPTB;MD6wN|Q4OyEQvF2= NVHLVlR6W0GQR1XS
HEC-1 M3fBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\ER25KSzVyPUCuNFM3QCEQvF2= NWixOWpGW0GQR1XS
SW756 NYnDPJRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEO4NlEh|ryP NYXJfZREW0GQR1XS
NCI-H64 NF;pPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMEO4OFIh|ryP NITIe4tUSU6JRWK=
EW-16 NUK1V49OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL4bGlbUUN3ME2wMlA{QTB7IN88US=> MXvTRW5ITVJ?
CAL-51 NHPTRolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMESwNFUh|ryP NGXnN4RUSU6JRWK=
KYSE-150 NEL6WWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW4SJdKSzVyPUCuNFQxOTFizszN MmHMV2FPT0WU
SW1710 NHKyR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1yxNWlEPTB;MD6wOFAyQCEQvF2= M4XudXNCVkeHUh?=
HuP-T4 NVfUTnNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXoTWM2OD1yLkC0NVE5KM7:TR?= M4PY[HNCVkeHUh?=
LB373-MEL-D NYH1cYFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLaUGFOUUN3ME2wMlA1OjN{IN88US=> M2PwSHNCVkeHUh?=
EW-13 NXTw[|M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMES0NFYh|ryP MXHTRW5ITVJ?
HT-29 Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXBTWM2OD1yLkC0OFkh|ryP MUTTRW5ITVJ?
SCC-25 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfLZmdKSzVyPUCuNFQ1QTRizszN NWXXZ20zW0GQR1XS
REH M1jvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXq[5VEUUN3ME2wMlA1PjN3IN88US=> M4\2eXNCVkeHUh?=
L-363 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnPeXdvUUN3ME2wMlA1Pjd7IN88US=> MoDaV2FPT0WU
NCI-H1770 NY\CS|ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G5XmlEPTB;MD6wOFY6PyEQvF2= MoPzV2FPT0WU
CHL-1 M4XrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3jW2ZKSzVyPUCuNFQ5PTdizszN M{HDVnNCVkeHUh?=
ES1 NEXGRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljBTWM2OD1yLkC0PFg2KM7:TR?= NVL1cmJMW0GQR1XS
SCC-15 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTmbplvUUN3ME2wMlA1QTB{IN88US=> MlSwV2FPT0WU
MRK-nu-1 NXLndVFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Hvc2lEPTB;MD6wOFk{PiEQvF2= NF;wVlZUSU6JRWK=
PF-382 MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLSTWM2OD1yLkC0PVM6KM7:TR?= M{L5dnNCVkeHUh?=
COLO-680N MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwMEWwOFch|ryP NXPocWxLW0GQR1XS
LK-2 M2LycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nHdmlEPTB;MD6wOVA3OyEQvF2= NVqyTnVUW0GQR1XS
NCI-H2342 NEDuSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rVO2lEPTB;MD6wOVEyPyEQvF2= M{nQWnNCVkeHUh?=
HMV-II M3r1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEizW3NKSzVyPUCuNFUzOzlizszN NYD2cY5pW0GQR1XS
PC-14 NYnmUWhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljQTWM2OD1yLkC1NlUzKM7:TR?= MkDuV2FPT0WU
COLO-320-HSR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\XclBKSzVyPUCuNFUzQDlizszN NF;ybFlUSU6JRWK=
697 M1fNNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDJTWM2OD1yLkC1N|I{KM7:TR?= M4jXfXNCVkeHUh?=
NEC8 M13keWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMEW1PUDPxE1? MkHLV2FPT0WU
LCLC-97TM1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fk[GlEPTB;MD6wOVU6PCEQvF2= NWTZfIZXW0GQR1XS
Daoy M{fwfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXtTWM2OD1yLkC1OlE3KM7:TR?= M3LmenNCVkeHUh?=
ETK-1 Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUP3[oxJUUN3ME2wMlA2Pjd{IN88US=> MX;TRW5ITVJ?
A388 M4HZ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;oOHp{UUN3ME2wMlA2Pjl3IN88US=> M3jyeXNCVkeHUh?=
COLO-205 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHG1O4VKSzVyPUCuNFU4OTZizszN M4C1SXNCVkeHUh?=
SK-PN-DW NUPLVm9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vEeGlEPTB;MD6wOVczQSEQvF2= NHPQO3RUSU6JRWK=
SF268 M{DjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjQeWhKSzVyPUCuNFU4PTZizszN M4T3TnNCVkeHUh?=
OCI-AML2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;QNVhKSzVyPUCuNFU4PzdizszN MlexV2FPT0WU
GAMG NXq5W3pvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPCW4xKSzVyPUCuNFU5KM7:TR?= MlK0V2FPT0WU
BCPAP NYLNfGZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zkOmlEPTB;MD6wOVg6OiEQvF2= NUL0[4o2W0GQR1XS
BC-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfVTWM2OD1yLkC2NFIzKM7:TR?= MYXTRW5ITVJ?
IA-LM MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHGdo9KSzVyPUCuNFYxPTNizszN NGnPd4tUSU6JRWK=
NCI-H1299 NHPVbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTBwME[xN{DPxE1? M1rYNnNCVkeHUh?=
COR-L23 NYfGVpc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXWOo9KSzVyPUCuNFYyOzRizszN NUjvXpV4W0GQR1XS
KYSE-180 NGrrUndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HHR2lEPTB;MD6wOlE1OiEQvF2= M3f3bnNCVkeHUh?=
LOXIMVI MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnBUHFiUUN3ME2wMlA3OTh6IN88US=> NXnVZXlwW0GQR1XS
BL-41 NV\KTm5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;wdGlEPTB;MD6wOlIyQSEQvF2= NFqwVY5USU6JRWK=
BL-70 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwME[zNFIh|ryP NUHHRXNqW0GQR1XS
NOS-1 MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7qTWM2OD1yLkC2OFEyKM7:TR?= M4DaeXNCVkeHUh?=
NB13 NX6wdIlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LlV2lEPTB;MD6wOlQzOSEQvF2= NVLPeZd1W0GQR1XS
CAL-27 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DHOmlEPTB;MD6wOlQ3PCEQvF2= NHuxZWVUSU6JRWK=
CA46 NXLhTld4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK5TWM2OD1yLkC2OVM4KM7:TR?= MkfGV2FPT0WU
SW962 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILWbllKSzVyPUCuNFY2PjlizszN M3LzbHNCVkeHUh?=
NCI-H226 MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\sO4ZwUUN3ME2wMlA3PjN{IN88US=> NE\SU|NUSU6JRWK=
KYSE-70 M1rzeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwME[5OFUh|ryP M1HHVnNCVkeHUh?=
Daudi M4e2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;SUYRwUUN3ME2wMlA4ODhzIN88US=> MWXTRW5ITVJ?
SW626 M1HpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrzTWM2OD1yLkC3NlA1KM7:TR?= M4H1OnNCVkeHUh?=
ESS-1 M2rSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PI[WlEPTB;MD6wO|I1PiEQvF2= MYHTRW5ITVJ?
YT M3jidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMEezOFUh|ryP MYTTRW5ITVJ?
P12-ICHIKAWA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDGTWM2OD1yLkC3N|Q6KM7:TR?= NYX4fXNWW0GQR1XS
BxPC-3 NFrufWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMEe0OVgh|ryP M1;JS3NCVkeHUh?=
CTV-1 MlrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHCTWM2OD1yLkC3OVE4KM7:TR?= NV\vOmVuW0GQR1XS
MLMA MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMEe1N|Qh|ryP NInndYhUSU6JRWK=
WSU-NHL M3OwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HsW2lEPTB;MD6wO|U2PCEQvF2= NHrnO2FUSU6JRWK=
CTB-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWiyfoszUUN3ME2wMlA4PTh6IN88US=> M4npbXNCVkeHUh?=
MMAC-SF M4\CT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[zWmlEPTB;MD6wO|Y3QCEQvF2= NYGxTpZ7W0GQR1XS
8-MG-BA MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTuZlJjUUN3ME2wMlA4QDBzIN88US=> MUPTRW5ITVJ?
NCI-H358 M4n6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3uOVJzUUN3ME2wMlA4QDd7IN88US=> MVnTRW5ITVJ?
BFTC-905 M{HURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwMEe5NFkh|ryP NHe4TnNUSU6JRWK=
NCI-H727 M4TDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH24b2pKSzVyPUCuNFgxPTNizszN M{\wdHNCVkeHUh?=
CHP-212 NVz1WGo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LzW2lEPTB;MD6wPFA6PSEQvF2= NFTZO2pUSU6JRWK=
HOP-62 NVHaR2U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrVOoZKSzVyPUCuNFgzPDVizszN NYX0RpVvW0GQR1XS
CESS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvvTWM2OD1yLkC4NlY6KM7:TR?= MljZV2FPT0WU
HuCCT1 NIHDdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn2TWM2OD1yLkC4N|M{KM7:TR?= M1W0SXNCVkeHUh?=
DEL NF;YfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLQ[nNqUUN3ME2wMlA5OzR5IN88US=> NHzFVGtUSU6JRWK=
5637 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMEizOlch|ryP NHjrXIpUSU6JRWK=
RS4-11 NXKwXoxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTaZYNnUUN3ME2wMlA5PDl5IN88US=> MoDTV2FPT0WU
KURAMOCHI M3T6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfkbmt5UUN3ME2wMlA5PTB7IN88US=> NFvudYhUSU6JRWK=
A427 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVziZYp1UUN3ME2wMlA5PTF{IN88US=> NITpfWxUSU6JRWK=
A3-KAW MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMEi1OlYh|ryP NWfUTopPW0GQR1XS
LS-123 MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLJZlRKSzVyPUCuNFg4OTlizszN MVrTRW5ITVJ?
LoVo Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn1TWM2OD1yLkC4O|Ih|ryP NXH2R5hyW0GQR1XS
PA-1 MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHKyeY5KSzVyPUCuNFg4PjlizszN MmXCV2FPT0WU
CP50-MEL-B Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4W2U2lEPTB;MD6wPFc6OyEQvF2= MlzHV2FPT0WU
A431 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jmTWlEPTB;MD6wPFgxOSEQvF2= MXzTRW5ITVJ?
HCT-116 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMEi4NFIh|ryP MYPTRW5ITVJ?
A4-Fuk MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMEi5OFch|ryP Ml\yV2FPT0WU
RPMI-6666 M3XsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TyPGlEPTB;MD6wPFk3PyEQvF2= Mo\GV2FPT0WU
Calu-6 NVr2UG1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlX1TWM2OD1yLkC5NFI6KM7:TR?= M4XtfXNCVkeHUh?=
KMOE-2 M4nvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXNNZRKSzVyPUCuNFkxOzlizszN MnnaV2FPT0WU
A704 NVq4VVV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMEmxOUDPxE1? MXPTRW5ITVJ?
HO-1-N-1 M3zBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr1cI9vUUN3ME2wMlA6OjR7IN88US=> NUHuWpVSW0GQR1XS
NCI-H2122 MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHtPFJHUUN3ME2wMlA6Ozd6IN88US=> M2G0Z3NCVkeHUh?=
U-698-M NGXPdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwMEm0NFkh|ryP NFLQd5JUSU6JRWK=
IST-SL2 NET2flVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEm0Olgh|ryP NIW3dphUSU6JRWK=
TE-10 Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKyTWM2OD1yLkC5OVg1KM7:TR?= MYjTRW5ITVJ?
PANC-03-27 M4PMWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\JUmlEPTB;MD6wPVY4OSEQvF2= MoPwV2FPT0WU
KYSE-410 MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33JRWlEPTB;MD6wPVc6PyEQvF2= MnmzV2FPT0WU
TE-8 NVSzbFNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMEm4PFUh|ryP NGS1WZlUSU6JRWK=
MN-60 M37WeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnqbpZKSzVyPUCuNFk5QTdizszN NILVPY9USU6JRWK=
NCI-H460 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzJTWM2OD1yLkGwNFkh|ryP MWDTRW5ITVJ?
LB771-HNC NXvUW4ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfwTWM2OD1yLkGwNlU2KM7:TR?= NFLlcphUSU6JRWK=
ES4 Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPqNJRKSzVyPUCuNVAzPjRizszN MWPTRW5ITVJ?
HUTU-80 NIG5bGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL2eYJKSzVyPUCuNVA{PjVizszN MXLTRW5ITVJ?
647-V MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPpcGpmUUN3ME2wMlExPDB6IN88US=> NGLtWGNUSU6JRWK=
HTC-C3 MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjucYV{UUN3ME2wMlExPDN{IN88US=> NU\MRVVyW0GQR1XS
NTERA-S-cl-D1 NF;RU|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwMUC0OFgh|ryP MUnTRW5ITVJ?
A2058 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7yW5dnUUN3ME2wMlExPjV3IN88US=> MkPXV2FPT0WU
MZ1-PC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMUC4N{DPxE1? M2fIZXNCVkeHUh?=
J82 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMUC4PFQh|ryP NUO1c4tmW0GQR1XS
ARH-77 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTtTWM2OD1yLkGxJO69VQ>? NHLQPHdUSU6JRWK=
Ca9-22 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHudZU1UUN3ME2wMlEyOTJ6IN88US=> NVvwPXIzW0GQR1XS
NCI-H1648 M3O1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSwXWJ{UUN3ME2wMlEyOjh4IN88US=> NV7aOGpNW0GQR1XS
MC116 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK1TWM2OD1yLkGxN|M4KM7:TR?= MYTTRW5ITVJ?
EoL-1-cell MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC0Z21KSzVyPUCuNVE1PjdizszN Ml3XV2FPT0WU
PANC-10-05 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPYfGtKSzVyPUCuNVE1QTFizszN MXvTRW5ITVJ?
SF539 MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWyTWM2OD1yLkGxOlE3KM7:TR?= MkG0V2FPT0WU
ES8 NWrTWFlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj6TWM2OD1yLkGxOlM{KM7:TR?= Mn;GV2FPT0WU
NCI-H810 NVLZWI54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVKzSJFJUUN3ME2wMlEyPjZ2IN88US=> MYDTRW5ITVJ?
J-RT3-T3-5 NWHjenZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;Le2lEPTB;MD6xNVc2KM7:TR?= NXXiOJNIW0GQR1XS
NY MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\mW2dKSzVyPUCuNVE5OTdizszN NHTSfIRUSU6JRWK=
NCI-SNU-1 MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPPe3JKSzVyPUCuNVIyPDhizszN MlLRV2FPT0WU
EFM-19 M3fKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMUKzO|Qh|ryP NV3xNFE2W0GQR1XS
HCC1806 M{XmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\4TWM2OD1yLkGyN|g{KM7:TR?= M3HndnNCVkeHUh?=
HCE-T M{PWbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwMUK1N|Eh|ryP NHfBdFNUSU6JRWK=
HT-1376 NWn0WXF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMUK2Olgh|ryP MmS1V2FPT0WU
BE-13 M37pfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMUK4OlYh|ryP NFX6NlBUSU6JRWK=
NCI-H520 Mo\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe4dnc1UUN3ME2wMlEzQDZ5IN88US=> NV62SmVCW0GQR1XS
SK-MES-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnXO5pKSzVyPUCuNVI6OTNizszN MX3TRW5ITVJ?
SNU-423 NXrCNWhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD3TWM2OD1yLkGyPVE1KM7:TR?= M{fwe3NCVkeHUh?=
Ramos-2G6-4C10 NU\aXYdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLwd|E{UUN3ME2wMlEzQTF4IN88US=> NYHZS3M1W0GQR1XS
EW-18 NYi3[m1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:we2lEPTB;MD6xN|AzPiEQvF2= NHS5d3NUSU6JRWK=
NCI-H2087 NGPPd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLBTWM2OD1yLkGzNFI4KM7:TR?= MnHaV2FPT0WU
COLO-792 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;yVmlKSzVyPUCuNVMyPjVizszN M{X1Z3NCVkeHUh?=
QIMR-WIL NW[3fHpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG3cogxUUN3ME2wMlE{OjJ|IN88US=> M3vmbHNCVkeHUh?=
ACHN MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XrNWlEPTB;MD6xN|I1PyEQvF2= NWO3VXFEW0GQR1XS
RPMI-8866 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e1[2lEPTB;MD6xN|I3OSEQvF2= MlLXV2FPT0WU
SK-LU-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:zTWM2OD1yLkGzOFQ6KM7:TR?= MXPTRW5ITVJ?
SK-UT-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\2bmlEPTB;MD6xN|YzQCEQvF2= M1L2VXNCVkeHUh?=
MFE-296 NXHleFl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMUO4OlQh|ryP MnLUV2FPT0WU
RD NFf3fJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFL5VVZKSzVyPUCuNVM6QTdizszN MkHGV2FPT0WU
LS-411N NGPkXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KxUGlEPTB;MD6xOFI6PSEQvF2= M4TycHNCVkeHUh?=
NCI-H747 M3;qZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwMUSzJO69VQ>? NFuxNlJUSU6JRWK=
ES6 Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3JNVNuUUN3ME2wMlE1OzZizszN NUjtT2pEW0GQR1XS
TE-1 MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jsNWlEPTB;MD6xOFQxPyEQvF2= NIPYT2xUSU6JRWK=
SJSA-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXZTWM2OD1yLkG0O|A4KM7:TR?= NWO1bFcyW0GQR1XS
NCI-H1355 NFnWd25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnKyTWM2OD1yLkG1Nlk{KM7:TR?= MUTTRW5ITVJ?
HEL NHH5d4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LQPGlEPTB;MD6xOVQ1PyEQvF2= NUXOW2NMW0GQR1XS
639-V MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj3V3lKSzVyPUCuNVU2QTZizszN Mom4V2FPT0WU
AN3-CA NITOT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfITWM2OD1yLkG1OlM6KM7:TR?= Mn2xV2FPT0WU
SK-MEL-2 NX\LRWxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTXc3NEUUN3ME2wMlE2PjZ6IN88US=> M1rofHNCVkeHUh?=
SW872 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfLTWM2OD1yLkG2NFQzKM7:TR?= Ml3TV2FPT0WU
DU-4475 MlfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nWVmlEPTB;MD6xOlE3OiEQvF2= M4L5OnNCVkeHUh?=
YKG-1 NGX2eFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknLTWM2OD1yLkG2Nlc{KM7:TR?= M3u5ZXNCVkeHUh?=
GT3TKB NFfnXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1u1bWlEPTB;MD6xOlI5OyEQvF2= M2jPc3NCVkeHUh?=
GB-1 NUTEOWtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTBwMU[0NlQh|ryP MmDxV2FPT0WU
KARPAS-422 M37tSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTUTWM2OD1yLkG2OVc1KM7:TR?= MYfTRW5ITVJ?
ATN-1 M4PJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrsTWM2OD1yLkG2OlU3KM7:TR?= MXvTRW5ITVJ?
HLE M1jpNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknOTWM2OD1yLkG2PFc4KM7:TR?= M2nWcnNCVkeHUh?=
D-542MG NYOzZXF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDETWM2OD1yLkG2PVg3KM7:TR?= MnvIV2FPT0WU
EB-3 MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLGRoVKSzVyPUCuNVc{OSEQvF2= M4SxbXNCVkeHUh?=
HCC1143 MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHiOVhKSzVyPUCuNVc{QTZizszN NX;reI5zW0GQR1XS
DJM-1 MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrETWM2OD1yLkG3OFUyKM7:TR?= MYPTRW5ITVJ?
BT-474 NGLyUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NED4bXdKSzVyPUCuNVc1QDlizszN NUj4e|JZW0GQR1XS
BB65-RCC Mm[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rseWlEPTB;MD6xO|U1PSEQvF2= NV;keIxCW0GQR1XS
NCI-H292 NUfOOoN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO1TWM2OD1yLkG3OlAyKM7:TR?= NUPGV3J3W0GQR1XS
MKN28 NFjGdWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m1NmlEPTB;MD6xO|Y2OyEQvF2= M2O2d3NCVkeHUh?=
TK10 NUnDXWluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwMUe3NFIh|ryP NH36XYZUSU6JRWK=
TYK-nu M4HBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTYXVl6UUN3ME2wMlE4QTR7IN88US=> MnvyV2FPT0WU
8305C NHrneGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDZOXhKSzVyPUCuNVc6PzFizszN NUTIbIdsW0GQR1XS
MV-4-11 Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTTTWM2OD1yLkG3PVc4KM7:TR?= MnuwV2FPT0WU
NCI-H522 M{jXcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfRcphuUUN3ME2wMlE5ODl2IN88US=> NYjFWplqW0GQR1XS
Hs-578-T NVjLcXEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXvOZF4UUN3ME2wMlE5Ojl{IN88US=> M1;XNHNCVkeHUh?=
LCLC-103H MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\qSGlEPTB;MD6xPFUzPyEQvF2= MVTTRW5ITVJ?
MHH-ES-1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDPTWM2OD1yLkG4OlI6KM7:TR?= NXPpU2RlW0GQR1XS
NCI-H441 MoO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwMUmxOFgh|ryP M3nxTHNCVkeHUh?=
AM-38 M4r3NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;jTWM2OD1yLkG5NlI2KM7:TR?= NEG1SpVUSU6JRWK=
SW1783 M3TD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nBNGlEPTB;MD6xPVMxPSEQvF2= NXLSNW5{W0GQR1XS
SK-HEP-1 M3\xOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHtfHhKSzVyPUCuNVk3OzdizszN Ml7KV2FPT0WU
OAW-28 NGjZVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH5TWM2OD1yLkKwNVc5KM7:TR?= NHfnbGFUSU6JRWK=
TE-15 M4\CSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH5TVlLUUN3ME2wMlIxOjV{IN88US=> M1\6N3NCVkeHUh?=
HCE-4 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jEc2lEPTB;MD6yNFI5PCEQvF2= MlrjV2FPT0WU
JiyoyeP-2003 NE\ufG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzMTWM2OD1yLkKwN|M3KM7:TR?= M3fibHNCVkeHUh?=
OVCAR-4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwMkC2Nlgh|ryP NEn0elJUSU6JRWK=
SNU-449 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NECwZZhKSzVyPUCuNlA4QTdizszN MVrTRW5ITVJ?
SBC-5 NXPKN2xFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHmeVMxUUN3ME2wMlIyOjF3IN88US=> NHzk[FdUSU6JRWK=
T84 NHu0[XpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnvTWM2OD1yLkKxNlQ5KM7:TR?= NXy4cFFXW0GQR1XS
LP-1 NIX5WHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7DepNKSzVyPUCuNlE{ODJizszN MmfZV2FPT0WU
MG-63 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LRbmlEPTB;MD6yNVM5OiEQvF2= Mn;rV2FPT0WU
OAW-42 M1zMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwMkG0O|gh|ryP MlP6V2FPT0WU
L-540 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW5TWM2OD1yLkKxOVk5KM7:TR?= MlHKV2FPT0WU
RH-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2SwXWlEPTB;MD6yNlI1OiEQvF2= NWezdGw5W0GQR1XS
HCT-15 NV23[|hkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHMfnlQUUN3ME2wMlIzPDh2IN88US=> M3vtRXNCVkeHUh?=
OCUB-M NEjrZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnSyTWM2OD1yLkKyOFg5KM7:TR?= MUnTRW5ITVJ?
GP5d MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moe5TWM2OD1yLkKyOVI5KM7:TR?= Mo\kV2FPT0WU
NCI-H2030 MlzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMkK3N|Qh|ryP NWPhUpdpW0GQR1XS
ML-2 Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DoTGlEPTB;MD6yNlg5QSEQvF2= Ml2yV2FPT0WU
CAL-39 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDid25KSzVyPUCuNlI6OzZizszN NHTEPIhUSU6JRWK=
MIA-PaCa-2 NEDnZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm0[ZlJUUN3ME2wMlI{Ojh5IN88US=> M3L3b3NCVkeHUh?=
TE-9 NFjHOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLlNGZuUUN3ME2wMlI{OzJizszN NH3CSWNUSU6JRWK=
LB2518-MEL MnK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnT0TWM2OD1yLkKzN|czKM7:TR?= Ml;iV2FPT0WU
DB NGXsVoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWroUVBNUUN3ME2wMlI{PDN6IN88US=> MVXTRW5ITVJ?
NCI-H596 NHLj[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zqXmlEPTB;MD6yN|U4OSEQvF2= NVLmOXJFW0GQR1XS
SW1990 Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\tPIZKSzVyPUCuNlM6PDZizszN NEi0[YNUSU6JRWK=
P30-OHK NYSyZ|d4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMkSwOUDPxE1? NX7heHFzW0GQR1XS
ALL-PO MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTCTWM2OD1yLkK0NVY6KM7:TR?= M3P0V3NCVkeHUh?=
Saos-2 NYLRVIZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XxNGlEPTB;MD6yOFU4OSEQvF2= M{DKO3NCVkeHUh?=
MFH-ino NYfNXGFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK3[JRKSzVyPUCuNlQ3QTJizszN NYDiNpRHW0GQR1XS
OE33 NHP5TmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvpTWM2OD1yLkK1NVEh|ryP MVXTRW5ITVJ?
Calu-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMkWyPVch|ryP NYDlcFROW0GQR1XS
HT MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nyZWlEPTB;MD6yOVYzOSEQvF2= MoHiV2FPT0WU
LXF-289 NEDMTlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHhTWM2OD1yLkK1PVg1KM7:TR?= MoK5V2FPT0WU
KGN MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMk[wPFkh|ryP NV;2XGJDW0GQR1XS
NCI-H1417 NV\2bnQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO4TWM2OD1yLkK2OVI1KM7:TR?= MXnTRW5ITVJ?
SF126 MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG4cYY2UUN3ME2wMlI4OzB{IN88US=> NV7Sc4R5W0GQR1XS
SAS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMkezNFgh|ryP M3;kVXNCVkeHUh?=
22RV1 M2DE[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH0TWM2OD1yLkK3N|c5KM7:TR?= MnnnV2FPT0WU
GI-1 MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LBWmlEPTB;MD6yO|Q5PyEQvF2= NVvrUo06W0GQR1XS
ES3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMke3OlMh|ryP NUPFc3BuW0GQR1XS
NB1 Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;iTWM2OD1yLkK3PFc3KM7:TR?= MU\TRW5ITVJ?
NCI-H650 M2OxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmK4TWM2OD1yLkK4N|AzKM7:TR?= M4\UZnNCVkeHUh?=
IST-MES1 M3nkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDLOYpKSzVyPUCuNlg2PTRizszN NH63W29USU6JRWK=
UM-UC-3 M1n1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XlcGlEPTB;MD6yPVE1KM7:TR?= MYPTRW5ITVJ?
CAL-120 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXrR29KSzVyPUCuNlk3OzFizszN M3ruTHNCVkeHUh?=
UACC-62 NWHodWZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLuTWM2OD1yLkOwNlQyKM7:TR?= NHHzNGlUSU6JRWK=
TE-11 Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTINGlXUUN3ME2wMlMxOjR7IN88US=> Ml7kV2FPT0WU
MKN1 M{jrPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDzTWM2OD1yLkOwN|Yh|ryP NG\6R3hUSU6JRWK=
KS-1 M4j4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK5TWM2OD1yLkOwOVI3KM7:TR?= MnrTV2FPT0WU
GCIY MkG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTZTWM2OD1yLkOxNFAzKM7:TR?= M3\oSHNCVkeHUh?=
OVCAR-5 NYi4U4txT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwM{GxNFYh|ryP NXv0T|V{W0GQR1XS
U-266 M4T4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLue5hiUUN3ME2wMlMyOTR5IN88US=> NI[3fGtUSU6JRWK=
Calu-1 NETxfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfqUFNKSzVyPUCuN|EzQDlizszN M{fTeXNCVkeHUh?=
SK-LMS-1 NV\UWZcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33KUWlEPTB;MD6zNVQzQSEQvF2= MmTwV2FPT0WU
COLO-741 NHfOd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjSUGlKSzVyPUCuN|E3OTRizszN MXnTRW5ITVJ?
RPMI-8226 MlToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwM{G2OFEh|ryP NHjtOXFUSU6JRWK=
KM12 MlfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXTTWM2OD1yLkOxPFMh|ryP Mlj3V2FPT0WU
NMC-G1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PlR2lEPTB;MD6zNVg3KM7:TR?= M4Xy[HNCVkeHUh?=
SJRH30 M4Xod2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\0TWM2OD1yLkOyNFUzKM7:TR?= M1jz[3NCVkeHUh?=
COR-L105 NFnke25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4r0fGlEPTB;MD6zNlIyQCEQvF2= NV25OFVZW0GQR1XS
IM-9 M3XVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjCN2tKSzVyPUCuN|MxOjFizszN NYTTeGs6W0GQR1XS
TE-12 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwM{OzNVch|ryP MXPTRW5ITVJ?
KG-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\JTWM2OD1yLkOzOFMzKM7:TR?= MW\TRW5ITVJ?
U251 NXnGUYdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPDOIFKSzVyPUCuN|M1PTZizszN NFzGeXJUSU6JRWK=
EFO-27 M3HqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrSVm1KSzVyPUCuN|M6PTFizszN M3\ubnNCVkeHUh?=
EW-24 MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwM{O5PFQh|ryP M1nRZXNCVkeHUh?=
SF295 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwM{O5PVkh|ryP NVXqbJdZW0GQR1XS
MC-IXC Ml\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwM{S1JO69VQ>? MX3TRW5ITVJ?
NCI-H2405 NUW0fFlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4n5TGlEPTB;MD6zOFc{OiEQvF2= MoTRV2FPT0WU
NCI-H2009 NXjqfWpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwM{S3N|kh|ryP MXnTRW5ITVJ?
LB1047-RCC NIDwfZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC5UYF5UUN3ME2wMlM2QDF3IN88US=> MonGV2FPT0WU
KNS-81-FD MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m0[2lEPTB;MD6zOlY3PyEQvF2= MYjTRW5ITVJ?
HOP-92 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;HfWlKSzVyPUCuN|Y5OyEQvF2= M2f3fXNCVkeHUh?=
L-428 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrLOHJKSzVyPUCuN|cxOTZizszN NULrZlB2W0GQR1XS
C3A NIjVPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jFbWlEPTB;MD6zO|M4QSEQvF2= M4nOOnNCVkeHUh?=
NCI-H1792 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDoTXVKSzVyPUCuN|c3PTVizszN NVfqU5pyW0GQR1XS
HuH-7 NFXiWYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X5c2lEPTB;MD6zO|kyKM7:TR?= NF76fIJUSU6JRWK=
AGS NX3Jcmc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXOTWM2OD1yLkO4OlM5KM7:TR?= MYfTRW5ITVJ?
HT-1197 MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwM{m0OkDPxE1? NV3XR5drW0GQR1XS
CGTH-W-1 Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXZUHNKSzVyPUCuN|k6OTNizszN NETOWZhUSU6JRWK=
KNS-42 M1n1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwNECwOFUh|ryP M1;kbnNCVkeHUh?=
HuO-3N1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\vepM4UUN3ME2wMlQxODV3IN88US=> M4fCV3NCVkeHUh?=
VMRC-RCZ MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXhO5p{UUN3ME2wMlQxOzB|IN88US=> NFy2bYZUSU6JRWK=
SW954 M2mwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3WUGgzUUN3ME2wMlQxOzN3IN88US=> NEjSSGVUSU6JRWK=
MES-SA MoD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfBRYxKSzVyPUCuOFA2ODVizszN MnnkV2FPT0WU
Ca-Ski MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vSeWlEPTB;MD60NFUzPCEQvF2= MU\TRW5ITVJ?
SW13 MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwNEC2NlYh|ryP M4TzenNCVkeHUh?=
NCI-H1437 Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrCV|lsUUN3ME2wMlQxQDB3IN88US=> MX;TRW5ITVJ?
U-118-MG MortS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fod2lEPTB;MD60NFkxPCEQvF2= M2e0OXNCVkeHUh?=
NCI-H1734 MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW4PYNKSzVyPUCuOFIxOTNizszN MVPTRW5ITVJ?
HDLM-2 NILwZ4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXmUIY6UUN3ME2wMlQzODN|IN88US=> M{nmNnNCVkeHUh?=
AU565 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonqTWM2OD1yLkSyOFY5KM7:TR?= M{fDdHNCVkeHUh?=
FADU MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPYTWM2OD1yLkSyOlQ6KM7:TR?= M{XtSHNCVkeHUh?=
OS-RC-2 M1Szbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXKV3RKSzVyPUCuOFMxQDNizszN NI\yZ4xUSU6JRWK=
CAMA-1 M37PXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjsb4xKSzVyPUCuOFM3OjZizszN NVrJTYhsW0GQR1XS
MONO-MAC-6 M2rnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLwTWM2OD1yLkSzPFQ6KM7:TR?= M1;xSnNCVkeHUh?=
LB831-BLC NWLy[mhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwNESzO|Eh|ryP M2jmXHNCVkeHUh?=
SW982 M3:0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDYR5U{UUN3ME2wMlQ1PTJ6IN88US=> MVfTRW5ITVJ?
SCC-3 NY\NVHVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\j[m1KSzVyPUCuOFQ2PzlizszN NXLzZnNHW0GQR1XS
C32 NGTOVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETWVYJKSzVyPUCuOFUzOjlizszN MYnTRW5ITVJ?
BFTC-909 M4PDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITXWoZKSzVyPUCuOFUzQTlizszN NGSwT5ZUSU6JRWK=
MEG-01 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwNEWzO|Mh|ryP NHnBc|BUSU6JRWK=
M14 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr6TWM2OD1yLkS1PVc6KM7:TR?= MkLOV2FPT0WU
MPP-89 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\iNWVKSzVyPUCuOFYzPTZizszN MUTTRW5ITVJ?
HCC1937 Ml7jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrpUZlqUUN3ME2wMlQ3Ozh2IN88US=> M3K1bnNCVkeHUh?=
SW837 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvrWpVKSzVyPUCuOFY4OjJizszN NVXlNHd2W0GQR1XS
DU-145 NYDRfnkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrrTWM2OD1yLkS2O|I6KM7:TR?= MlrGV2FPT0WU
LB996-RCC NHm0PVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3i5SmlEPTB;MD60O|A2PCEQvF2= MnLYV2FPT0WU
C8166 NWOw[IVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y2UWlEPTB;MD60O|Qh|ryP NVS2S41SW0GQR1XS
MOLT-4 NHTuV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC4TWM2OD1yLkS3O|M1KM7:TR?= NIDjPHJUSU6JRWK=
DMS-53 MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fLWGlEPTB;MD60O|gxQSEQvF2= MXXTRW5ITVJ?
TE-5 M2faPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTBwNEizNFUh|ryP MU\TRW5ITVJ?
KYSE-520 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[yTWM2OD1yLkS4N|Q{KM7:TR?= MX3TRW5ITVJ?
Detroit562 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\tR3dKSzVyPUCuOFg5PiEQvF2= NFfWR4NUSU6JRWK=
SIMA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjKT4c6UUN3ME2wMlQ6PDF5IN88US=> M1PtSHNCVkeHUh?=
NCI-H1651 NEXNXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO4TXd5UUN3ME2wMlQ6PjdizszN NWPVO5lVW0GQR1XS
HCC1599 NYC2WnVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwNEm5OVUh|ryP MVvTRW5ITVJ?
ABC-1 MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwNUC0PVYh|ryP NGrzfIdUSU6JRWK=
CAL-33 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPnTWM2OD1yLkWwPFQ1KM7:TR?= NHntWpJUSU6JRWK=
OPM-2 NHq2[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P0ZWlEPTB;MD61NFk{PyEQvF2= Mm\0V2FPT0WU
RPMI-7951 NVTUb|V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwNUC5OVch|ryP M{\O[nNCVkeHUh?=
HT-1080 NXrINFl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3ZZ3dKSzVyPUCuOVEyOTlizszN MnX1V2FPT0WU
LC4-1 M{XVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzZTWM2OD1yLkWxOFA{KM7:TR?= NXHLW5VbW0GQR1XS
OVCAR-3 NWH3WZl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:2N2lEPTB;MD61NVU4KM7:TR?= M{S1RnNCVkeHUh?=
CAPAN-1 M4DENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwNUKyPFgh|ryP NYDxXWxkW0GQR1XS
SK-OV-3 M2n2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkT2TWM2OD1yLkWyOFM1KM7:TR?= Mn;tV2FPT0WU
HuP-T3 MnS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3QTWM2OD1yLkWyPFI4KM7:TR?= MoGzV2FPT0WU
NCI-H838 NVr1bXJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ntTGlEPTB;MD61Nlg1QSEQvF2= NUXGb2tsW0GQR1XS
K5 M2f2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwNUOyNFEh|ryP MWDTRW5ITVJ?
CAL-72 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWn4XFFFUUN3ME2wMlU{Ozh5IN88US=> MXXTRW5ITVJ?
NH-12 NX7qTWdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M365UGlEPTB;MD61N|k2QSEQvF2= MnPTV2FPT0WU
SNB75 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjrUGhKSzVyPUCuOVU4OyEQvF2= M1fseHNCVkeHUh?=
BPH-1 NWDOSHBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwNU[zOFQh|ryP M4LzSXNCVkeHUh?=
NOMO-1 NEH2[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk[0TWM2OD1yLkW2N|czKM7:TR?= MWLTRW5ITVJ?
G-402 NGn6dYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwNU[0PVkh|ryP MVTTRW5ITVJ?
NCI-H2052 NHvCNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XaV2lEPTB;MD61Olc1OSEQvF2= NFWzPI1USU6JRWK=
RCM-1 MnixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHGTWM2OD1yLkW3NVY3KM7:TR?= M4G5d3NCVkeHUh?=
COR-L279 NWK0e5RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDpTWM2OD1yLkW3NVg2KM7:TR?= MVzTRW5ITVJ?
A253 Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwNUe1NlUh|ryP NF;OS3VUSU6JRWK=
SK-MM-2 NVnrWnM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNUe2O|kh|ryP NVLzRYtqW0GQR1XS
NCI-H1703 NHz2NHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwNUm0Nlch|ryP M3PPOHNCVkeHUh?=
UACC-257 M3TGNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwNUm0PFch|ryP MmW0V2FPT0WU
KALS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwNkCwNVEh|ryP MorhV2FPT0WU
ES5 NX\LTnFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXXNGNvUUN3ME2wMlYxPDhizszN M4i4UHNCVkeHUh?=
MHH-CALL-2 NUnRVWljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnxPHRKSzVyPUCuOlA5QDhizszN MlG0V2FPT0WU
ChaGo-K-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwNkGyNlkh|ryP NVHyUlY{W0GQR1XS
TGBC1TKB M4D1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknYTWM2OD1yLk[xPVgh|ryP NGXIZVJUSU6JRWK=
KU-19-19 NGPN[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwNkS1PFYh|ryP NH\zTHRUSU6JRWK=
COLO-684 NX\DbY05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELkO|lKSzVyPUCuOlU3OTFizszN NGLtfIVUSU6JRWK=
LS-1034 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwNkW4NVkh|ryP Mlr6V2FPT0WU
RT-112 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLZTWM2OD1yLk[2OVg4KM7:TR?= NUPWZnc{W0GQR1XS
Capan-2 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHiTWM2OD1yLk[2OlIzKM7:TR?= MVTTRW5ITVJ?
HSC-4 NVz6WJRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPzZoZKSzVyPUCuOlY3QThizszN MVHTRW5ITVJ?
COLO-824 M2na[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHlNGlOUUN3ME2wMlY4QDJ|IN88US=> MojjV2FPT0WU
NCI-H2170 NEPPfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwNkiyOVgh|ryP M4SwTnNCVkeHUh?=
GDM-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInkWoRKSzVyPUCuOlg1QTRizszN M3v0cnNCVkeHUh?=
KP-4 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwNkm1O|Mh|ryP Mn3CV2FPT0WU
VA-ES-BJ MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmW3TWM2OD1yLk[5PVg3KM7:TR?= MVzTRW5ITVJ?
KM-H2 NXe2bXR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf2TWM2OD1yLkewNFkyKM7:TR?= MorJV2FPT0WU
HH NH7TVY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwN{C2OlIh|ryP MUnTRW5ITVJ?
DK-MG NVTI[FBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LVPWlEPTB;MD63NVAyPiEQvF2= MnTDV2FPT0WU
VM-CUB-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILqV3VKSzVyPUCuO|EzPTlizszN NXXTSXBIW0GQR1XS
COLO-829 MkDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVS2Z4wyUUN3ME2wMlcyQTh3IN88US=> NEHMTJlUSU6JRWK=
OMC-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnBV2pDUUN3ME2wMlczOTB2IN88US=> NVLBSVM5W0GQR1XS
NB12 M3SwfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LBc2lEPTB;MD63NlUxPCEQvF2= MU\TRW5ITVJ?
NCI-H28 NIDuZXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfEOoxVUUN3ME2wMlc1ODh|IN88US=> MUPTRW5ITVJ?
A673 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTrc|lvUUN3ME2wMlc2OTd5IN88US=> MUjTRW5ITVJ?
LB2241-RCC NVXLRmk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXVc|BKSzVyPUCuO|YxQDdizszN M{Prc3NCVkeHUh?=
CCRF-CEM M2LOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPj[HhKSzVyPUCuO|cxPTJizszN MVLTRW5ITVJ?
NCI-H510A M3LIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwN{exPFYh|ryP NVzyUGNlW0GQR1XS
SW48 NHK0OVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnRTWM2OD1yLke3N|M{KM7:TR?= NXWzUldKW0GQR1XS
NCI-H2081 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHac3pKSzVyPUCuO|gyPDdizszN M3HzW3NCVkeHUh?=
RMG-I MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHJendWUUN3ME2wMlc5OjF{IN88US=> MWLTRW5ITVJ?
LU-99A M4ftXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnL3TWM2OD1yLke4OFE{KM7:TR?= NHryVIlUSU6JRWK=
KP-N-YS MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[1TWM2OD1yLke4PVIyKM7:TR?= MmOyV2FPT0WU
MDA-MB-231 NITIVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTBwOECxN|Eh|ryP MYnTRW5ITVJ?
U031 MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnCd5NKSzVyPUCuPFE1OjNizszN NEHBUYZUSU6JRWK=
EVSA-T NXPVZnRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorXTWM2OD1yLkixOlczKM7:TR?= NG[wNnVUSU6JRWK=
MDA-MB-157 MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M170bGlEPTB;MD64NlI4OSEQvF2= NGrXdodUSU6JRWK=
EHEB M2LhNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULWXmx5UUN3ME2wMlgzOjd4IN88US=> MoPiV2FPT0WU
KINGS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37uXWlEPTB;MD64NlU2PSEQvF2= MnPEV2FPT0WU
23132-87 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwOEK4OFMh|ryP NX23eGt{W0GQR1XS
EFO-21 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\CO20xUUN3ME2wMlg1ODh7IN88US=> NELsV4lUSU6JRWK=
DOK M2q0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwOES4JO69VQ>? NYTFWGlvW0GQR1XS
NCI-H2171 M37vNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn5fJFKSzVyPUCuPFQ6PiEQvF2= NX;pdlBTW0GQR1XS
NCI-SNU-5 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGixZ5dKSzVyPUCuPFU2PyEQvF2= MVfTRW5ITVJ?
SK-N-DZ NGXmdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TydGlEPTB;MD64OVk1OyEQvF2= Mn[4V2FPT0WU
SNU-C2B NVHUTplrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwOE[4NFEh|ryP MlvZV2FPT0WU
CP66-MEL M1LGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwOEexNUDPxE1? MkXjV2FPT0WU
SN12C NIn5e4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvWc|BVUUN3ME2wMlg5PjN5IN88US=> MV\TRW5ITVJ?
A172 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPjTWM2OD1yLki4Olk5KM7:TR?= MoHjV2FPT0WU
NCI-H2347 NYjFSHJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi5fnEzUUN3ME2wMlg5PzV|IN88US=> NGjHOIZUSU6JRWK=
NCI-H2228 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTBTWM2OD1yLki5N|M6KM7:TR?= MnHPV2FPT0WU
SNU-387 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn36TWM2OD1yLkmwNlY1KM7:TR?= MnvQV2FPT0WU
SK-MEL-24 NVrsc5I2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXOUndlUUN3ME2wMlkyOzR2IN88US=> M2LxSnNCVkeHUh?=
MDA-MB-468 NFTwUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vRc2lEPTB;MD65NVc{KM7:TR?= M2WwVXNCVkeHUh?=
NCI-H1694 M4rONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PsdGlEPTB;MD65NVg4PiEQvF2= NYX0cpY4W0GQR1XS
CCF-STTG1 NHPZbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7YfYxKSzVyPUCuPVI3OzdizszN M3[zOXNCVkeHUh?=
K052 NXvyc|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm3d5ZKSzVyPUCuPVQxPDdizszN NEHZcmhUSU6JRWK=
NCI-H446 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnlcoFTUUN3ME2wMlk2ODFizszN MYfTRW5ITVJ?
MFE-280 NHL0e3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDSTWM2OD1yLkm2NlkyKM7:TR?= Mn3RV2FPT0WU
KU812 NVvoXGhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nZZ2lEPTB;MD65PVM5QSEQvF2= NE[4XlBUSU6JRWK=
MDA-MB-361 NYPjV5NST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXIXoRzUUN3ME2wMlk6Pzd5IN88US=> M2HrcnNCVkeHUh?=
Raji NYLhZ5V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn65TWM2OD1zLkCyNlY4KM7:TR?= MljmV2FPT0WU
TE-6 NIX3fINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDOR4VKSzVyPUGuNFM2PjZizszN MVfTRW5ITVJ?
CAL-148 NELYSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGOzXpVKSzVyPUGuNFQ1PDNizszN M{LoUXNCVkeHUh?=
NCI-H1963 M3z2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrRS21KSzVyPUGuNFQ2PTNizszN NGDo[pRUSU6JRWK=
SK-N-AS NV3qZXlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfHPZRmUUN3ME2xMlA1Pjh3IN88US=> MXTTRW5ITVJ?
RERF-LC-MS NIroNXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTFwME[zOFkh|ryP NXvCUm5jW0GQR1XS
BEN NHG2eohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDjS3N5UUN3ME2xMlA4OTN5IN88US=> NUXkOIo1W0GQR1XS
CAS-1 MoPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFwMEmxNlMh|ryP MmS3V2FPT0WU
SW780 M4TSVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LDdWlEPTB;MT6wPVE5OSEQvF2= NXmwTY1TW0GQR1XS
LU-65 NYfnUpZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFwMEm0NUDPxE1? NXfOPHh6W0GQR1XS
D-283MED M2roT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHmdYdYUUN3ME2xMlEzOjd{IN88US=> M3HnVHNCVkeHUh?=
HCC2157 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwMUO2OFIh|ryP NHr4c4RUSU6JRWK=
RCC10RGB NHnkZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\BdXNqUUN3ME2xMlE1ODB4IN88US=> NIjUPYpUSU6JRWK=
PLC-PRF-5 NVW2R|ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M376fWlEPTB;MT6xOVIzQSEQvF2= MUXTRW5ITVJ?
H4 M1G5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTFwMUW0N|kh|ryP MljQV2FPT0WU
TUR Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nOfmlEPTB;MT6xOVc2OiEQvF2= M{T4fHNCVkeHUh?=
NCI-H2141 NFjiXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFznXndKSzVyPUGuNVg6PDZizszN MXrTRW5ITVJ?
PFSK-1 NULs[5VNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LJT2lEPTB;MT6yNFU{OiEQvF2= NVeyVVdwW0GQR1XS
SK-MEL-28 M3nhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTZTWM2OD1zLkKzNlIyKM7:TR?= Mn[zV2FPT0WU
SCC-9 MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfGZ|NKSzVyPUGuNlM3PjVizszN MlrsV2FPT0WU
T47D NIDVcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTFwMkO2PVYh|ryP MWLTRW5ITVJ?
TCCSUP M2naTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jtUWlEPTB;MT6yOVAzQSEQvF2= MVPTRW5ITVJ?
SU-DHL-1 NFPkOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7w[XppUUN3ME2xMlI2OTF6IN88US=> NWHMeHlLW0GQR1XS
HL-60 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2T1TmlEPTB;MT6yOVU5QCEQvF2= M4n3TXNCVkeHUh?=
NCI-H1436 M4rnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M176RWlEPTB;MT6yOlE1QSEQvF2= NG\RZVBUSU6JRWK=
DMS-114 NFjLd3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XVc2lEPTB;MT6yOlY{OiEQvF2= MXTTRW5ITVJ?
BOKU MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXCR2hXUUN3ME2xMlI5ODl3IN88US=> MVHTRW5ITVJ?
MS-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHNZoVMUUN3ME2xMlI6ODZ7IN88US=> MUDTRW5ITVJ?
NCI-H661 NXn1UHA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTFwM{C0O|gh|ryP NWfyWXNJW0GQR1XS
HT-3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPvTJRCUUN3ME2xMlMxPTJ7IN88US=> M1fzRXNCVkeHUh?=
CAL-54 M17v[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\TTWM2OD1zLkOwO|I2KM7:TR?= M3fQdnNCVkeHUh?=
SW1463 NFXWUJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHLSZFKSzVyPUGuN|E5PzJizszN MWHTRW5ITVJ?
COLO-668 NYHibIVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXGcHNUUUN3ME2xMlM{ODV4IN88US=> NIDYWJNUSU6JRWK=
PANC-08-13 M3fpNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq1NZZKSzVyPUGuN|M5ODNizszN M17FT3NCVkeHUh?=
BB49-HNC M{jKNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwM{SwNUDPxE1? NGHldYhUSU6JRWK=
M059J MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTFwM{W4N|Ih|ryP M4jxc3NCVkeHUh?=
NCCIT NYjHdVc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTFwM{e5PFgh|ryP MVHTRW5ITVJ?
LN-405 NFH1TJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CxcWlEPTB;MT6zPVI3PCEQvF2= MVXTRW5ITVJ?
UMC-11 Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorVTWM2OD1zLkO5PVk3KM7:TR?= NWj4[Gp6W0GQR1XS
NB5 M3LlOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fXNWlEPTB;MT60NVIzPyEQvF2= M2O4TXNCVkeHUh?=
TE-441-T MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjSTWM2OD1zLkSyPFE4KM7:TR?= Mk[xV2FPT0WU
ME-180 NIH4d4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT6[3pKSzVyPUGuOFQ{QTJizszN Mn\pV2FPT0WU
HCC70 M2jWVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37vU2lEPTB;MT60OlA6PiEQvF2= MmLnV2FPT0WU
no-10 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwNE[xPFEh|ryP MYfTRW5ITVJ?
JEG-3 M2fGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvQTWM2OD1zLkWwNVMzKM7:TR?= MoHsV2FPT0WU
no-11 NFvqNHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwNUC4PFIh|ryP M{WyfHNCVkeHUh?=
CHP-126 M1vNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\rRWlEPTB;MT61OlY6OSEQvF2= NVrkTGxoW0GQR1XS
EGI-1 Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XXe2lEPTB;MT61PFAzPSEQvF2= M1qwNXNCVkeHUh?=
D-392MG NFGwSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[1UldRUUN3ME2xMlU6PjNizszN NIDMWINUSU6JRWK=
RT4 M2eydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fzcGlEPTB;MT61PVY{PyEQvF2= NHm1ZXRUSU6JRWK=
A204 NXeyT2pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDvXVVHUUN3ME2xMlU6QDBzIN88US=> M1LFPXNCVkeHUh?=
NCI-H1304 M2foXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnvWolKSzVyPUGuOlM2QTFizszN MWrTRW5ITVJ?
Becker MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPjfXk3UUN3ME2xMlY1OjRzIN88US=> MmXMV2FPT0WU
OE19 M3u4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\RTWM2OD1zLk[1OVE5KM7:TR?= MWTTRW5ITVJ?
EKVX NXvhd4VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rTfmlEPTB;MT62OVYyQCEQvF2= NH22OG1USU6JRWK=
KLE M17nVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLBeFdHUUN3ME2xMlY2PzF2IN88US=> M1HzNXNCVkeHUh?=
K-562 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvOTWM2OD1zLk[3NFM4KM7:TR?= MWfTRW5ITVJ?
MDA-MB-175-VII M4Ww[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLkfpNFUUN3ME2xMlY5QTl5IN88US=> NVHQOFhDW0GQR1XS
NCI-H716 NWfPZmxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLjSmk4UUN3ME2xMlY6OzB2IN88US=> M{P4XnNCVkeHUh?=
Caov-3 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwNkm0NVMh|ryP NFnxXFdUSU6JRWK=
HCC1187 M2XTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnftTWM2OD1zLkewOVQ2KM7:TR?= MWnTRW5ITVJ?
CAKI-1 MnTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPsTGxKSzVyPUGuO|IzQTJizszN MVPTRW5ITVJ?
MOLT-16 NV20bFZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXaWGtKSzVyPUGuO|M{ODdizszN M3PVTHNCVkeHUh?=
PC-3 NIm1NJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwN{WwPEDPxE1? M4C1O3NCVkeHUh?=
DV-90 NEXncoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\yNINtUUN3ME2xMlc2PTh3IN88US=> M3noOHNCVkeHUh?=
RXF393 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\TeZFKSzVyPUGuO|czQTRizszN M4O1TnNCVkeHUh?=
SK-NEP-1 M33kSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\CSZBKSzVyPUGuPFI{OzlizszN MV\TRW5ITVJ?
HCC1419 NI\ldXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnSxTWM2OD1zLkiyOlkzKM7:TR?= M2fXZnNCVkeHUh?=
BV-173 NWrFSWVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFwOEK5PVUh|ryP MluyV2FPT0WU
MKN7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwOEmyNkDPxE1? MWDTRW5ITVJ?
LAN-6 NF75PItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFwOEm1OVMh|ryP MXPTRW5ITVJ?
Mo-T M{fTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\pTWM2OD1zLkmwNFM6KM7:TR?= NHX6co9USU6JRWK=
HCC1395 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTFwOUK4OlMh|ryP NVvHT3ZsW0GQR1XS
HC-1 M4nDTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTFwOUO0O{DPxE1? M4HRcHNCVkeHUh?=
HPAF-II MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF20RWpKSzVyPUGuPVQ1OThizszN M2W3c3NCVkeHUh?=
CPC-N M4D5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4izdmlEPTB;MT65PFAxOiEQvF2= M4rhbHNCVkeHUh?=
MKN45 M1rrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Pvc2lEPTB;MT65PVEyQSEQvF2= NHPycZdUSU6JRWK=
NCI-H1693 M{m2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmqzTWM2OD1{LkCwOFM{KM7:TR?= NUfS[pA3W0GQR1XS
SHP-77 NVrjdlFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnxeFJ1UUN3ME2yMlAxPTN|IN88US=> MoflV2FPT0WU
NCI-H1522 MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW3Rmd6UUN3ME2yMlAyPzJ2IN88US=> NWXmRm1xW0GQR1XS
SW1573 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljLTWM2OD1{LkCyNkDPxE1? NWDY[3doW0GQR1XS
DBTRG-05MG NWTQS4NJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJwME[wPFch|ryP MVHTRW5ITVJ?
SCC-4 MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXLTWM2OD1{LkG0N|Eh|ryP NVjVdllUW0GQR1XS
DMS-153 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnK2TWM2OD1{LkG2OlY5KM7:TR?= M3y1N3NCVkeHUh?=
MDA-MB-415 M3fkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLHT4Y2UUN3ME2yMlE4PTJizszN NHnuSFRUSU6JRWK=
NCI-H2126 NY[0WohKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L1dmlEPTB;Mj6yNlg5QCEQvF2= NGPCUWNUSU6JRWK=
MDA-MB-453 M3HLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr0VWVKSzVyPUKuNlM{OiEQvF2= MlK4V2FPT0WU
U-87-MG NVrWNog4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvHTWM2OD1{LkK4OVkzKM7:TR?= NEjtOnZUSU6JRWK=
LNCaP-Clone-FGC M{PlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJwM{CxNFIh|ryP NVXOPWpGW0GQR1XS
NCI-H1581 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXKzSZI4UUN3ME2yMlMzOTB3IN88US=> MVPTRW5ITVJ?
BC-3 NX3oc|NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv6T|VKSzVyPUKuN|Y2ODlizszN NYfZTnRZW0GQR1XS
HCC38 NGX5SnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEf4cYxKSzVyPUKuN|g1PDdizszN MX3TRW5ITVJ?
HCC2218 MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIru[29KSzVyPUKuOFA5ODlizszN MX\TRW5ITVJ?
RO82-W-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rKUmlEPTB;Mj60NVI2KM7:TR?= NGHvb2pUSU6JRWK=
C2BBe1 NHKzNoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJwNEG1O|gh|ryP NGHpXo1USU6JRWK=
LAMA-84 NGe0ToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEX0bWRKSzVyPUKuOVc{PjhizszN MWfTRW5ITVJ?
GMS-10 MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHHeII1UUN3ME2yMlU4PjFzIN88US=> MV\TRW5ITVJ?
GCT M1TrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3i1eGlEPTB;Mj61PFY6PCEQvF2= NGC4bYpUSU6JRWK=
SK-CO-1 NUXMbpFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ra[GlEPTB;Mj62NVY3KM7:TR?= MXnTRW5ITVJ?
NCI-H526 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfO[opKSzVyPUKuOlM1PSEQvF2= NWfmWoRiW0GQR1XS
SW1088 MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJwN{e4N|kh|ryP MXLTRW5ITVJ?
HT55 MofRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPmT2JKSzVyPUKuO|g3QTVizszN Ml:1V2FPT0WU
NB10 MlTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljsTWM2OD1{LkixO|Q5KM7:TR?= M4fZdHNCVkeHUh?=
UACC-893 M{f2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\ON|BOUUN3ME2yMlg2PzR7IN88US=> NYrObmhnW0GQR1XS
NCI-H1618 NF\JVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXy[Is5UUN3ME2yMlg5OTV|IN88US=> MUTTRW5ITVJ?
NCI-H1092 M2HQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnYTolKUUN3ME2zMlA4QDF{IN88US=> NIHPNFFUSU6JRWK=
SBC-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXzTWM2OD1|LkC4OVU{KM7:TR?= MWTTRW5ITVJ?
NCI-H1623 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rPWWlEPTB;Mz6wPVM1KM7:TR?= MULTRW5ITVJ?
SiHa M4fKSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ScJJ7UUN3ME2zMlEyQTd5IN88US=> M3PPd3NCVkeHUh?=
D-263MG NIjWb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTNwMUS3PFgh|ryP NX60eYozW0GQR1XS
NCI-H1573 Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDZPWJKSzVyPUOuNVk3PDFizszN MYrTRW5ITVJ?
NCI-H82 NYD1XIEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm[zTWM2OD1|LkO0OFM6KM7:TR?= NEPyWpFUSU6JRWK=
NCI-H2196 MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNwM{WwNFgh|ryP MVfTRW5ITVJ?
MFM-223 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorlTWM2OD1|LkO3N|UyKM7:TR?= NESwdIFUSU6JRWK=
COLO-678 M1jzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDQTWM2OD1|LkO4NVg3KM7:TR?= NVfqXHN6W0GQR1XS
EW-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\qbpdKSzVyPUOuOFA6PSEQvF2= MXvTRW5ITVJ?
MHH-NB-11 MoGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLWTWM2OD1|LkS0NFY6KM7:TR?= NHLjXHRUSU6JRWK=
EM-2 MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7vblRlUUN3ME2zMlY{QThizszN NX60TW1MW0GQR1XS
FTC-133 NXrPO5NzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3MZnlIUUN3ME2zMlY2PDV6IN88US=> NHXPN4JUSU6JRWK=
NCI-H209 MkTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTNwNke2OVMh|ryP MlrRV2FPT0WU
TGBC24TKB MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIm0eWFKSzVyPUOuOlg{PTVizszN Mnn3V2FPT0WU
LC-1F NHr0V2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[3cmlEPTB;Mz63NVc3PCEQvF2= Mn;2V2FPT0WU
C-4-II MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHuxbWlKSzVyPUOuO|U3PDNizszN NVHGSXBJW0GQR1XS
NCI-H1650 NGnVd4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjsNItKUUN3ME2zMlc5PDV3IN88US=> M{faPXNCVkeHUh?=
JVM-2 Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\nfmdpUUN3ME2zMlk{PjN7IN88US=> NEPW[3RUSU6JRWK=
CaR-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LRdWlEPTB;Mz65O|YyPyEQvF2= NEXpSWpUSU6JRWK=
MDA-MB-134-VI M2HJe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTTUWQ6UUN3ME20MlAzQTV{IN88US=> M2\teHNCVkeHUh?=
NCI-H719 Ml\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH2e4RKSzVyPUSuNVU{QDhizszN M{fmWHNCVkeHUh?=
GOTO NGLlbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTRwMkm3NFUh|ryP MlHPV2FPT0WU
NCI-N87 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f0[WlEPTB;ND6zPFgzOSEQvF2= Ml;JV2FPT0WU
NB6 NYX5bWx4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPqN2FKSzVyPUSuOFI2ODlizszN MWHTRW5ITVJ?
DSH1 NXLXTZFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGK1dFNKSzVyPUSuOFcyOTZizszN NEDnNmZUSU6JRWK=
BT-20 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGi1VJhKSzVyPUSuOFkxODJizszN MkfKV2FPT0WU
NCI-H1882 MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIO0TGtKSzVyPUSuOVA2PyEQvF2= NHP3NZBUSU6JRWK=
WM-115 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTRwNUC4PFEh|ryP NUP3foNMW0GQR1XS
SKG-IIIa NVLjcWR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDJSm5KSzVyPUSuOlc4PyEQvF2= MoD1V2FPT0WU
NCI-H69 M2fpTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\yXmlEPTB;ND63NFI4PSEQvF2= NHjzTnJUSU6JRWK=
MSTO-211H MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LuUWlEPTB;ND64N|U3PSEQvF2= NFfUV4lUSU6JRWK=
Mewo MkTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnBdpZKSzVyPUSuPVY{OTNizszN MYrTRW5ITVJ?
GI-ME-N NI\KcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zy[mlEPTB;NT6wNFUxQSEQvF2= NE\LOppUSU6JRWK=
T98G NYfhSFNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy0eZNKSzVyPUWuNFY2ODhizszN MULTRW5ITVJ?
ECC4 M37P[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfmR3FKSzVyPUWuNFk{PzJizszN NXjIUHZXW0GQR1XS
EW-11 NF[2eWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T6PWlEPTB;NT6xPFA6QSEQvF2= MmP0V2FPT0WU
COLO-800 NEnkSJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\GTWM2OD13LkG5N|Q6KM7:TR?= M2XIZ3NCVkeHUh?=
NCI-H1755 NWjmWFlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fhUWlEPTB;NT6yN|AzPyEQvF2= M3;jeHNCVkeHUh?=
KMS-12-PE MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3SUYxKSzVyPUWuN|UxQDVizszN NF[weoxUSU6JRWK=
HCC1954 NXjJOVh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvKd5o1UUN3ME21Mlg2QTdzIN88US=> M{\VT3NCVkeHUh?=
NCI-H187 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTVwOUK5PFkh|ryP NF;BSnhUSU6JRWK=
LU-165 NIjLXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrPOGpKSzVyPUWuPVkxODJizszN Mnr2V2FPT0WU
YAPC M{jRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[2dol1UUN3ME21Mlk6ODZ6IN88US=> NGPmTGNUSU6JRWK=
LU-139 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfMTWpKSzVyPU[uNFg{PjhizszN NWKxboFVW0GQR1XS
D-502MG M3;CSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrTeYFKSzVyPU[uN|IxPDdizszN NXrKZYg4W0GQR1XS
IST-SL1 NH30XZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTZwNUO5OFgh|ryP Mlv3V2FPT0WU
DG-75 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zMXGlEPTB;Nj64PFc5PiEQvF2= NXGzRW9ZW0GQR1XS
NCI-H1155 M{fhSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTZwOUW1PFEh|ryP Mm\pV2FPT0WU
EFE-184 NUHQTmdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rWNWlEPTB;Nz6zNVY6PSEQvF2= M2O1ZXNCVkeHUh?=
AsPC-1 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfSbJl3UUN3ME23MlQ5QDB5IN88US=> M2LiW3NCVkeHUh?=
SW948 M{DFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvMOmx[UUN3ME23MlU5Ozl3IN88US=> M2L2[3NCVkeHUh?=
NCI-H524 NYrVc|hRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTlwNUi2Nlgh|ryP MkjiV2FPT0WU
KOSC-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTlwNkK4N|Qh|ryP MlfsV2FPT0WU
T-24 M3HOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTlwOUS0NVUh|ryP NYDhZmVzW0GQR1XS
NCI-H748 M1vMNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfnflBKSzVyPUGwMlY{QTdizszN NGLnbG9USU6JRWK=
NCI-H23 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37QNGlEPTB;MUCuOlQ1OiEQvF2= Ml;QV2FPT0WU
UACC-812 NYDiWG1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTuZYFKSzVyPUGxMlcyPyEQvF2= MojFV2FPT0WU
SCLC-21H MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;jTWM2OD1zMj6xOVUyKM7:TR?= MWHTRW5ITVJ?
NCI-SNU-16 MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3OwOmlEPTB;MUOuNVI2QCEQvF2= M{XDXHNCVkeHUh?=
HD-MY-Z M{j1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS4TWM2OD1zND62N|Y{KM7:TR?= NETjVHFUSU6JRWK=
SK-N-FI NWTWd29yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzwT4VKSzVyPUG0Mlg6OTJizszN MYDTRW5ITVJ?
LB647-SCLC NWLRUJRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLRSlVjUUN3ME2xOU44OTl3IN88US=> M1T2cHNCVkeHUh?=
NCI-H345 NVvNVpRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDlTWM2OD1zNz6zOFMh|ryP M{jjWHNCVkeHUh?=
NCI-H1563 M1jTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfBPIV5UUN3ME2xPE44PjBzIN88US=> MVLTRW5ITVJ?
RL NFXZTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1G1UWlEPTB;MkGuNlY2PiEQvF2= MmexV2FPT0WU
KY821 NXHH[JVuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXoeXlXUUN3ME2yNk4xPTV|IN88US=> NFu1bG9USU6JRWK=
JVM-3 M4fmXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm4RXlKSzVyPUK1MlA1OTNizszN M1W3dHNCVkeHUh?=
NCI-H1793 NFL1T|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\FXHp6UUN3ME2yPE42PDl7IN88US=> MlLiV2FPT0WU
LU-134-A M{PaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTNyLkKwN|ch|ryP M3G1fXNCVkeHUh?=
NCI-H1395 NV3BcZJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELXOoJKSzVyPUOyMlI1OzFizszN M{H0S3NCVkeHUh?=
NCI-H1993 M3;z[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN{LkiyNVgh|ryP M2[xXXNCVkeHUh?=
P31-FUJ M2foVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTN|LkS4PVkh|ryP M1rodXNCVkeHUh?=
LS-513 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfhTWM2OD1|NT64PFc6KM7:TR?= M4XPfHNCVkeHUh?=
SK-MEL-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGL6ZVBKSzVyPUSwMlM1QTlizszN M3nEUXNCVkeHUh?=
SW684 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLDWmYzUUN3ME20N{46PjZzIN88US=> MX\TRW5ITVJ?
COR-L88 M4i0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjLTWM2OD12ND6wOlY2KM7:TR?= MWnTRW5ITVJ?
NCI-H889 NU\WbJgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTR3LkCwPFch|ryP NI[zVFhUSU6JRWK=
TALL-1 NYDRVINMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR4LkGxPVkh|ryP NXrab5BwW0GQR1XS
KARPAS-299 Mle4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PpbmlEPTB;NEeuNVk6OyEQvF2= MmTlV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]

Protocol

Kinase Assay:[1]
+ Expand

Bcl-2 Binding affinity calculation:

A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:[2]
+ Expand
  • Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
  • Concentrations: ~10 μM
  • Incubation Time: 48-72 hours
  • Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
  • Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m
  • Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg
  • Administration: Administered intravenously (tail vein) once a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.73 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.49
Formula

C20H19N3O.CH4O3S

CAS No. 803712-79-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT00918931 Terminated Leukemia|Systemic Mastocytosis M.D. Anderson Cancer Center|Gemin X June 2009 Phase 2
NCT00933985 Terminated Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific National Cancer Institute (NCI) June 2009 Phase 1
NCT00719901 Terminated Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma National Cancer Institute (NCI) July 2008 Phase 1|Phase 2
NCT00724841 Terminated Metastatic Melanoma Gemin X|Teva Pharmaceutical Industries June 2008 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) supplier | purchase Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) cost | Obatoclax Mesylate (GX15-070) manufacturer | order Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID